{
    "clinical_study": {
        "@rank": "127888", 
        "arm_group": [
            {
                "arm_group_label": "SKI3246 Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: Drug: SKI3246 Low Dose"
            }, 
            {
                "arm_group_label": "SKI3246 High Dose", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: Drug: SKI3246 High Dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intervention: Drug: Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy and safety of different doses of\n      SKI3246 compared with placebo in the treatment of patients with irritable bowel syndrome\n      with non-constipation."
        }, 
        "brief_title": "Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-constipation Irritable Bowel Syndrome", 
        "condition_browse": {
            "mesh_term": "Irritable Bowel Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have been diagnosed as non-constipation by ROME III.\n\n          -  Patients who voluntarily signed written informed consent may participate in the\n             study.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating female.\n\n          -  Patients with a history of inflammatory bowel disease.\n\n          -  Severe neurological or psychological disease\n\n          -  History of allergic reaction to the medications used in this study\n\n          -  Use of other investigational drugs within 30 days prior to the study.\n\n          -  Patients that investigators consider ineligible for this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "279", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079675", 
            "org_study_id": "SKI3246_IBS_II_2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "SKI3246 Low Dose", 
                "description": "SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening", 
                "intervention_name": "SKI3246 Low Dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SKI3246 High Dose", 
                "description": "SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening", 
                "intervention_name": "SKI3246 High Dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "SK Chemicals"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Ministry of Food and Drug Safety", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Global Assessment of Relief During the Double-Blind Treatment Phase Using the Subject Global Assessment (SGA)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient satisfaction using 5- Likert Scale", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Subject Self Reported Adequate Relief of Pain", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Mean Change From Baseline in Quality of Life as Measured by the Medical Outcomes Survey", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "SK Chemicals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "SK Chemicals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}